Rudisile, S., Gosewisch, A., Wenter, V., Unterrainer, M., Böning, G., Gildehaus, F. J., . . . Ilhan, H. (2019). Salvage PRRT with (177)Lu-DOTA-octreotate in extensively pretreated patients with metastatic neuroendocrine tumor (NET): Dosimetry, toxicity, efficacy, and survival. BMC Cancer.
Citação norma ChicagoRudisile, S., et al. "Salvage PRRT With (177)Lu-DOTA-octreotate in Extensively Pretreated Patients With Metastatic Neuroendocrine Tumor (NET): Dosimetry, Toxicity, Efficacy, and Survival." BMC Cancer 2019.
MLA CitationRudisile, S., et al. "Salvage PRRT With (177)Lu-DOTA-octreotate in Extensively Pretreated Patients With Metastatic Neuroendocrine Tumor (NET): Dosimetry, Toxicity, Efficacy, and Survival." BMC Cancer 2019.
Advarsel: Disse citationer er muligvist ikke 100% nøjagtige.